Keros Therapeutics Inc represents a strong set of values and corporate philosophy. The company is dedicated to developing innovative therapies that address significant unmet needs in the field of rare diseases and cancer. Keros Therapeutics Inc prioritizes scientific rigor, collaboration, and patient-centricity in every aspect of their work. By leveraging their expertise and cutting-edge research, they aim to deliver transformative treatments that improve patients' lives. Keros Therapeutics Inc's commitment to excellence, integrity, and empathy drives their mission to make a lasting impact in the healthcare industry.

Keros Therapeutics Inc is primarily present in the United States.

Keros Therapeutics Inc has achieved several significant milestones in its history. The company successfully completed its initial public offering (IPO) in August 2020, raising approximately $96 million in gross proceeds. Additionally, Keros Therapeutics Inc has received numerous grants and awards for its innovative research and development efforts focused on novel protein therapeutic candidates. The company has also formed strategic collaborations with leading biopharmaceutical companies to advance its pipeline and expand its scientific capabilities. Notably, Keros Therapeutics Inc initiated a Phase 1 clinical trial for its lead candidate, KER-050, in May 2020, demonstrating its progress towards developing potentially groundbreaking treatments for blood disorders and other hematological conditions.

Keros Therapeutics Inc is a biotechnology company specialized in developing therapies for severe diseases. Founded in [year], the company focuses on researching and designing novel protein-targeted therapeutics. With a primary focus on modulating the transforming growth factor-beta (TGF-β) superfamily, Keros Therapeutics aims to address various medical conditions, including hematologic, musculoskeletal, fibrotic, and oncologic diseases. By leveraging its extensive expertise in protein science, medicinal chemistry, and computational biology, the company seeks to unlock innovative treatment options for patients in need. Keros Therapeutics Inc continues to drive advancements in biotechnology by designing and developing disease-modifying therapeutics with the potential to improve patient outcomes and quality of life.

The main competitors of Keros Therapeutics Inc in the market are other companies operating in the field of biopharmaceuticals, particularly those focusing on the development of therapeutics for hematological and musculoskeletal disorders. Some notable competitors include Amgen Inc, Gilead Sciences Inc, and Pfizer Inc. These companies share a similar market niche and are actively engaged in developing novel therapies to address unmet medical needs. However, Keros Therapeutics Inc distinguishes itself by its unique approach and innovative pipeline targeting specific diseases.

Keros Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Keros Therapeutics Inc is a biotechnology company with a unique business model focused on the discovery and development of innovative therapeutics. The company utilizes its proprietary technology platform to leverage the understanding of protein structure and function in order to identify and target novel disease pathways. By targeting specific protein interactions, Keros Therapeutics aims to develop therapeutics for diseases with high unmet medical needs, including cancer, immunology, and genetic disorders. Through its research and development efforts, Keros Therapeutics Inc aims to bring transformative treatments to patients and create long-term value for its stakeholders.

مُعامل القيمة السوقية إلى الأرباح لـ Keros Therapeutics هو ؜-٩٫٠٩.

مُعامِل القيمة إلى المبيعات Keros Therapeutics هو ٧٤٨٫٦٢.

نقاط جودة AlleAktien لـ Keros Therapeutics هي 3/10.

المتوقعة Keros Therapeutics الإيرادات هي ٢٫٢٨ مليون. USD.

صافي الربح المتوقعة Keros Therapeutics هو ؜-١٨٧٫٩٨ مليون. USD.

Keros Therapeutics Inc. is a biopharmaceutical company focused on the development of small molecules for the treatment of serious diseases. The company utilizes its expertise in structural biology and chemistry to develop novel drugs with the potential to change lives.

يوزع Keros Therapeutics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Keros Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـKeros Therapeutics هو US4923271013.

رمز WKN لـ Keros Therapeutics هو A2P2YF.

الرمز المُختصر لـ Keros Therapeutics هو KROS.

خلال آخر 12 شهراً، دفعت Keros Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Keros Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Keros Therapeutics هي .

Keros Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Keros Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Keros Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Keros Therapeutics المُعلن عنها في ١‏/١١‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١‏/١١‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/١١‏/٢٠٢٤.

في العام 2023، وزعت Keros Therapeutics 0 USD كأرباح أسهم.

يتم توزيع أرباح Keros Therapeutics بالعملة USD.